Vimarsana
Biggest News Aggregation in the World

Page 43 - Blue Chips News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Blue Chips. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Blue Chips Today - Breaking & Trending Today

Delta Electronics: Delta Showcases Smart Energy Solutions for Low-Carbon Grids and Energy Transition at The Smarter E Europe - Vimarsana News

Delta Electronics: Delta Showcases Smart Energy Solutions for Low-Carbon Grids and Energy Transition at The Smarter E Europe

HANNOVER, Germany, June 8, 2023 /PRNewswire/ -- Delta, a global leader in power and thermal management solutions, announces its participation at The Smarter E Europe in Munich to demonstrate

Results of the initial public offering of Grab2Go AS shares - Vimarsana News

Results of the initial public offering of Grab2Go AS shares

The initial public offering of the shares of Grab2Go AS (registry code 16014547 hereinafter Grab2Go) ended on 6th June 2023. Up to 992,000 shares were publicly offered, whereas Grab2Go reserved the right to

A SPECTACULAR DISPLAY OF STARDOM & CELEBRATION OF INDIAN CINEMA AT THE 23rd EDITION OF IIFA WEEKEND AND AWARDS 2023 - Vimarsana News

A SPECTACULAR DISPLAY OF STARDOM & CELEBRATION OF INDIAN CINEMA AT THE 23rd EDITION OF IIFA WEEKEND AND AWARDS 2023

A WEEKEND OF CINEMA, MUSIC, FASHION, AND CULTURE LIGHTING UP THE GOLDEN SHORES OF ABU DHABI WITH OVER 25,000 PEOPLE IN ATTENDANCE OVER THE TWO DAYS, AT THE LARGEST STATE-OF-THE-ART INDOOR ENTERTAINMENT

ObsEva SA: Annual General Meeting 2023 - Vimarsana News

ObsEva SA: Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland - June 8, 2023 - ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for

Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma - Vimarsana News

Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Data demonstrate a significant 71% reduction in risk of disease progression or death in selinexor + bortezomib + dexamethasone (SVd) arm versus bortezomib + dexamethasone (Vd) arm in PI-naïve